Abstract 944: Pre-clinical activity of the Wnt pathway inhibitor RXC004 in combination with MAPK pathway inhibitors in GI cancer modelsSimon A. Woodcock, C. W. Phillips, Eimear Flanagan et al.|Cancer Research|2024Cited by 1
Abstract 1654: Pre-clinical activity of the Wnt/Beta-catenin pathway inhibitor RXC004 in models of biliary tract cancerSimon A. Woodcock, Caroline Phillips, Dorottya Keppel et al.|Cancer Research|2023Cited by 0